Medical Services

Clinical Trials at Englewood Hospital: Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

- Please scroll down to view all studies -

EHMC IRB Study #: E-14-543

Principal Investigator:
Dr. Michael Schleider
Tel: 201-568-5250
Email: MSCHLEIDE@aol.com

Study Coordinator:
Christine Paolillo
Tel: 201-568-6653
Email:chris.paolillo@ehmc.com

Sponsor:
Celgene

Study Title:
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Eligibility requirements:
Patients who are at least 18 years old with newly diagnosed myelodysplastic syndrome (MDS) or 55 years old with newly diagnosed acute myeloid leukemia (AML) are eligible.

Study objectives:
To describe current and evolving patterns for diagnosis, treatment, clinical monitoring and outcome measure in patients with high risk or low risk MDS and AML.

Summary of procedures:
Consenting patients will have data entered into the registry at baseline and then on a quarterly basis for up to 8 years, patient withdrawal, or study closure - whichever occurs first.

###

*Each listing only contains a summary of the study information. Please contact the Principal Investigator or Study Coordinator for the full details on a particular study.